Table 1.
Modified release oral liquid dosage forms—an overview of available formulations with paediatric license and drugs with finished clinical trials being under approval registration process by the Food and Drug Administration (FDA).
| Product (Manufacturer) | Drug | Dosage Form | Polymer (MR Technique) | Paediatric Licence | Indication | References |
|---|---|---|---|---|---|---|
| Delsym® (Reckitt Benckiser LLC.) | dextromethorphan | extended-release suspension | ion exchange resin drug/polymer complexation | ≥4 year | Cough | [36] |
| Dyanavel XR (TrisPharma) | amphetamine | extended-release suspension | sodium polystyrene sulfonate drug/polymer complexation | ≥6 years | attention-deficit hyperactivity disorder (ADHD) | [37] |
| MST® Continus® (Napp Pharmaceuticals Limited) | morphine | prolonged-release suspension | cationinc exchange resin drug/polymer complexation | ≥1 year | Pain | [38] |
| Quillivant XR (Pfizer) | methylphenidate | extended-release suspension | sodium polystyrene sulfonate drug/polymer complexation | ≥6 years | ADHD | [39] |
| Tussionex®(UCB) | Hydrocodone chlorpheniramine | extended-release suspension | ion exchange resin drug/polymer complexation microparticles | ≥6 years | common cold, flu | [40] |
| Zmax® (Pfizer) | azithromycin | extended-release suspension | glyceryl behenate and poloxamer 407 microspheres | ≥6 month | bacterial infections | [41] |
| under approval registration process by FDA | bupivacaine | NA * | SABER™ Delivery System in situ gel formation | NA * | local anesthetic | [42,43,44] |
| under approval registration process by FDA | methylphenidate | NA * | ORADUR™ in situ gel formation | NA * | pain | [45,46] |
| under approval registration process by FDA | mirabegron | sustained-release suspensions | microspheres with lauryl sulfate salt/complex | NA * | urinary incontinence | [47,48] |
| under approval registration process by FDA (Remoxy®) | oxycodone | NA * | ORADUR™ in situ gel formation | NA * | Pain | [49,50,51] |
* NA: no data available.